The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

On 05/11/2022, Teva Pharmaceuticals USA Inc. (Teva USA) initiated a voluntarily nationwide recall of a single lot of **Anagrelide Capsules, USP 0.5 mg** to the retail level in the United States. This recall has now been extended to the **Consumer/User Level**. As previously communicated, the affected product lot number GD01090 was distributed under the label of Teva Pharmaceuticals USA, Inc. No other lots are impacted.

NDC	Lot	Exp. Date	Size	Teva USA Distribution
0172-5241-60	GD01090	05/2022	100 Capsules/Bottle	07/30/2020 - 09/02/2020

As stated in our 05/11/2022 recall communication, this recall has been initiated because dissolution results for routine stability testing of lot number GD01090 are below approved specification limits. Administration of this product with lower dissolution – taking longer to dissolve once ingested -- may result in decreased effectiveness or ineffectiveness of the drug to exert its platelet-reducing effect. Failed dissolution can result in a slower rate and extent of drug release leading to less anagrelide available in the body. For seriously ill patients with elevated platelet counts, less available anagrelide in the body could increase the risk of clotting (blood coagulation), and clotting or bleeding events such as a heart attack or stroke, which could be life threatening. To date, Teva has not received any product quality complaints or adverse event reports, of this nature, for the recalled lot.